文献速递关节外科

全髋与全膝关节置换术中单剂静脉氨甲环酸与两剂等效

One Dose of Intravenous Tranexamic Acid Is Equivalent to Two Doses in Total Hip and Knee Arthroplasty.
PubMed 文献 · J Bone Joint Surg Am · 2018-01-01

研究纳入2012至2016年行全髋关节置换术(THA)1736例和全膝关节置换术(TKA)2042例患者,比较未用、单剂与两剂静脉氨甲环酸(TXA)在血红蛋白下降、异体输血率和并发症上的差异。结果显示单剂与两剂TXA在THA和TKA术后血红蛋白下降及输血率上效果相当,且不增加并发症。

要点

  • THA中单剂与两剂TXA术后平均血红蛋白下降相似(2.9 g/dL与3.1 g/dL,p=0.197),均小于未用组(3.6 g/dL,p<0.001)。
  • TKA中单剂与两剂TXA术后平均血红蛋白下降相似(2.4 g/dL与2.4 g/dL,p=0.891),均小于未用组(2.9 g/dL,p<0.001)。
  • THA输血率:未用组12.5%,单剂组0%,两剂组0.7%;TKA输血率:未用组4.3%,单剂组0.4%,两剂组0.3%;各组围手术期并发症发生率相似。

核心结论

  • 单剂TXA在减少THA和TKA术后失血及输血率方面与两剂同样有效,且不增加并发症。

研究设计与样本

  • 研究识别了2012至2016年行THA的1736例患者(未用TXA 592例、单剂TXA 454例、两剂TXA 690例)和行TKA的2042例患者(未用TXA 744例、单剂TXA 499例、两剂TXA 799例),评估组间血红蛋白水平变化、异体输血率和并发症率的差异。
  • 证据等级:治疗性III级。

主要发现

  • THA中单剂组与两剂组术后平均血红蛋白下降相似(2.9 g/dL与3.1 g/dL,p=0.197),均小于未用组(3.6 g/dL,p<0.001 vs 单剂组和两剂组),多因素分析控制年龄、性别和术前血红蛋白水平后结果一致。
  • THA输血率:未用组12.5%,单剂组0%,两剂组0.7%。
  • TKA中单剂组与两剂组术后平均血红蛋白下降相似(2.4 g/dL与2.4 g/dL,p=0.891),均小于未用组(2.9 g/dL,p<0.001 vs 单剂组和两剂组),多因素分析控制年龄、性别和术前血红蛋白水平后结果一致。
  • TKA输血率:未用组4.3%,单剂组0.4%,两剂组0.3%。
  • 所有组围手术期并发症发生率相似。

关键数值与推荐

  • THA术后平均血红蛋白下降:单剂组2.9 g/dL vs 两剂组3.1 g/dL(p=0.197),未用组3.6 g/dL(p<0.001 vs 单剂组和两剂组)。
  • TKA术后平均血红蛋白下降:单剂组2.4 g/dL vs 两剂组2.4 g/dL(p=0.891),未用组2.9 g/dL(p<0.001 vs 单剂组和两剂组)。
  • THA输血率:未用组12.5%,单剂组0%,两剂组0.7%。
  • TKA输血率:未用组4.3%,单剂组0.4%,两剂组0.3%。

临床怎么用

  • 原文结论为单剂TXA在减少THA和TKA术后失血及输血率方面与两剂同样有效,且不增加并发症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tranexamic acid (TXA) helps to prevent excessive blood loss during total hip arthroplasty (THA) and total knee arthroplasty (TKA), but the most efficacious dosing protocol has not been ascertained. The purpose of this study was to identify whether 1 dose of intravenous TXA is equivalent to 2 doses for reducing blood loss and transfusion rates following THA and TKA without an increase in complications. METHODS: We identified 1,736 patients who underwent THA (592 who did not receive TXA, 454 who received 1 dose of TXA, and 690 who received 2 doses) and 2,042 patients who underwent TKA (744 who did not receive TXA, 499 who received 1 dose, and 799 who received 2 doses) from 2012 to 2016. The differences among groups with regard to the change in hemoglobin levels, rate of allogeneic blood transfusions, and rate of complications were assessed. RESULTS: Patients who underwent THA and received 1 dose or 2 doses of TXA had similar drops in the mean hemoglobin levels postoperatively (2.9 g/dL and 3.1 g/dL, respectively; p = 0.197) and both had a smaller drop than the control group (3.6 g/dL; p < 0.001 compared with the 1 and 2-dose groups). These findings were confirmed by a multivariate analysis that controlled for age, sex, and preoperative hemoglobin level. Transfusion was required for 12.5% of the patients who underwent THA without receiving TXA, no patient who received 1 dose, and 0.7% of the patients who received 2 doses. The patients who underwent TKA and received 1 dose or 2 doses of TXA had similar mean drops in the hemoglobin level postoperatively (2.4 g/dL and 2.4 g/dL, respectively; p = 0.891), and both had less of a drop than the control group (2.9 g/dL; p < 0.001 compared with the 1 and 2-dose groups). These findings were also confirmed by a multivariate analysis that controlled for age, sex, and preoperative hemoglobin level. Transfusion was required for 4.3% of the patients who underwent TKA without receiving TXA, 0.4% of those who received 1 dose, and 0.3% of those who received 2 doses. Similar rates of perioperative complications occurred among all groups. CONCLUSIONS: One dose of TXA was as effective as 2 doses for decreasing blood loss and transfusion rates after THA and TKA without an increase in complications. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Wilde JM, Copp SN, McCauley JC, et al. One Dose of Intravenous Tranexamic Acid Is Equivalent to Two Doses in Total Hip and Knee Arthroplasty. J Bone Joint Surg Am. 2018. PMID: 29975264. doi:10.2106/JBJS.17.00641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。